Sofinnova News
Video: Sofinnova Partners 2024 annual general meeting
Related Strategy
CapitalRelated Strategy
CrossoverRelated Strategy
MD StartRelated Strategy
Digital MedicineRelated Strategy
Industrial BiotechRelated Strategy
TelethonRelated Strategy
BiovelocitaOur Annual General Meeting is a pivotal event that underscores the importance of collaboration and innovation in navigating our changing world, particularly in the current climate.
During this year's two-day event, our LPs, investment teams, and the CEOs of our portfolio companies shared stories of passion, perseverance, and the relentless pursuit of innovation to improve the health of people and the planet. These highlights remind us of the fundamentals we uphold in this period of constant change and uncertainty.
We extend our deepest gratitude to our LPs for their unwavering trust and support throughout the years. Their belief in our mission enables us to continue investing in groundbreaking science and innovation, which are essential in addressing our ever-changing world.
Check-out the video to get a glimpse of our 2024 Annual General Meeting:
Video of Sofinnova Partners 2024 Annual General Meeting
Related News
Elevara Medicines Raises $70 Million Series A to Advance Phase 2 Rheumatoid Arthritis Trial and Expand Pipeline
Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson’s disease candidate MTX325 through clinical trials
Verley becomes first company to receive FDA "No Questions Letter" for functionalized dairy Proteins made via precision fermentation
NanoPhoria Bioscience secures €83.5 Million Series A to advance breakthrough heart failure therapy and expand portfolio for novel Nano-in-Micro delivery platform
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease